Chemotherapy for non-clear-cell renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 4, Issue 4, 2006, Pages 263-268

  David, Kevin A ^a   Milowsky, Matthew I ^a   Nanus, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Collecting duct carcinoma; Papillary renal cell carcinoma; Sarcomatoid renal cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MESNA; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PANITUMUMAB; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SORAFENIB; VASCULOTROPIN; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION X; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLLECTING DUCT CARCINOMA; DOSE RESPONSE; FATIGUE; HUMAN; KIDNEY CARCINOMA; KIDNEY COLLECTING TUBULE; MUCOSA INFLAMMATION; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PAPILLARY CARCINOMA; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 33646873759     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.005     Document Type: Review

References (48)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623.
3. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005; 31:536-545.
4. van den Berg E, van der Hout AH, Oosterhuis JW, et al. Analysis of epithelial renal-cell tumors: relationship with a new histopathological classification. Int J Cancer 1993; 55:223-227.
5. Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol 1995; 103:624-635.
6. Storkel S, Steart PV, Drenckhahn D, et al. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 56:237-245.
7. Akhtar M, Kardar H, Linjawi T, et al. Chromophobe cell carcinoma of the kidney: a clinicopathologic study of 21 cases. Am J Surg Pathol 1995; 19:1245-1256.
8. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994; 145:356-364.
9. Reuter VE, Presti JC. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000; 27:124-137.
10. Nanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004; 101:1545-1551.
11. Stadler WM. Therapeutic options for variant renal cancer: a true orphan disease. Clin Cancer Res 2004; 10:6393s-6396s.
12. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376-2381.
13. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303-321.
14. Yu DS, Chang SY, Ma CP. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines. Br J Urol 1998; 82:544-547.
15. Bleumer I, Oosterwijk E, De Mulder P, et al. Immunotherapy for renal cell carcinoma. Eur Urol 2003; 44:65-75.
16. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma (RCC) response to interleukin-2-based therapy. Proc Am Soc Clin Oncol 2003; 22:851 (Abstract #3420).
17. Dimopoulos MA, Logothetis CJ, Markowitz A, et al. Collecting duct carcinoma of the kidney. Br J Urol 1993; 71:388-391.
18. Fleming S, Lewi HJ. Collecting duct carcinoma of the kidney. Histopathology 1986; 10:1131-1141.
19. Matz LF, Latham BI, Fabian VA, et al. Collecting duct carcinoma of the kidney: a report of three cases and review of the literature. Pathology 1997; 29:354-359.
20. Milowsky MI, Rosmarin A, Tickoo SK, et al. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 2002; 94:111-116.
21. Schoenberg M, Cairns P, Brooks JD, et al. Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer 1995; 12:76-80.
22. Takle LA, Knowles MA. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 1996; 12:1083-1087.
23. Selli C, Amorosi A, Vona G, et al. Retrospective evaluation of c-erbB-2 oncogene amplification using competitive per in collecting duct carcinoma of the kidney. J Urol 1997; 158:245-247.
24. Gollob JA, Upton MP, DeWolf WC, et al. Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 2001; 58:1058i-1058iii.
25. Strobel T, Kraeft SK, Chen LB, et al. Bax expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for bax during chemotherapy-induced cell death. Cancer Res 1998; 58:4776-4781.
26. Peyromaure M, Thiounn N, Scotte F, et al. Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 2003; 170:1138-1140.
27. Cohen HT, McGovern FJ. Renal cell carcinoma. N Eng J Med 2005; 353:2477-2490.
28. Noguera-Irizarry WG, Hibshoosh H, Papadopoulos K. Renal medullary carcinoma: case report and review of the literature. Am J Clin Oncol 2003; 26:489-492.
29. De Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 2001; 25:275-284.
30. Mian BM, Bhadkamkar N, Slaton JW, et al. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167:65-70.
31. Escudier B, Droz JP, Rolland MJ, et al. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase III study of the genitourinary group of the french federation of cancer centers. J Urol 2002; 168:959-961.
32. Bangalore N, Bhargava P, Hawkins MJ, et al. Sustained response of sarcomatoid renal cell carcinoma to MAID chemotherapy: case report and review of the literature. Annal Oncol 2001; 12:271-274.
33. Lupera H, Theodore C, Ghosn M, et al. Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer. Urology 1989; 34:281-283.
34. Sella A, Logothetis CJ, Ro JY, et al. Sarcomatoid renal-cell carcinoma. A treatable entity. Cancer 1987; 60:1313-1318.
35. Culine S, Bekradda M, Terrier-LaCombe MJ, et al. Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy? Eur Urol 1995; 27:138-141.
36. Hoshi S, Satoh M, Ohyama C, et al. Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma. Int J Clin Onrol 2003; 8:113-117.
37. Mejean A, Hopirtean V, Bazin JP, et al. Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 2003; 170:764-767.
38. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the met proto-oncogene in papillary renal carcinomas. Nat Genet 1997; 16:68-73.
39. Sweeney P, El-Naggar A, Lin S, et al. Biologic significance of c-met over expression in papillary renal cell carcinoma. J Urol 2002; 168:51-55.
40. Morris MR, Gentle D, Abdulrahman M, et al. Tumor suppresor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/spint2 in papillary and clear cell renal cell carcinoma. Cancer Res 2005; 65:4598-4606.
41. Eble JN, Sauter G, Epstein JI, et al. World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
42. Sangkhathat S, Kusafuka T, Yoneda A, et al. Renal cell carcinoma in a pediatric patient with an inherited mitochondrial mutation. Pediatr Surg Int 2005; 12:1-4.
43. Pérot C, Boccon-Gibod L, Bouvier R, et al. Five new cases of juvenile renal cell carcinoma with translocations involving xp11.2: a cytogenetic and morphologic study. Cancer Gen Cytogen 2003; 143:93-99.
44. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med 2005; 25:363-378.
45. Salles PG, Soto M Jr. Kidney carcinoma associated with Xp11.2 translocation/TFE3 (ASPL-TFE3) gene fusion. Int Braz J Urol 2005; 31:251-255.
46. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003; 27:612-624.
47. Peyromaure M, Misrai V, Thiounn N, et al. Chromophobe renal cell carcinoma: analysis of 61 cases. Cancer 2004; 100:1406-1410.
48. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-3015.